Richard F. Ambinder

Richard F. Ambinder

Oncology

401 North Broadway Street, Weinberg BLDG
Weinberg BLDG
Baltimore, MD 21287

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 182 publications

The Biology and Clinical Utility of EBV Monitoring in Blood.

The Biology and Clinical Utility of EBV Monitoring in Blood.

Journal: Current topics in microbiology and immunology

Published: February 03, 2026

EBV INFECTION OUTCOMES DETERMINED BY MONOCYTE AND TREG-DRIVEN IMMUNE DYNAMICS IN AN EX VIVO PBMC MODEL.

EBV INFECTION OUTCOMES DETERMINED BY MONOCYTE AND TREG-DRIVEN IMMUNE DYNAMICS IN AN EX VIVO PBMC MODEL.

Journal: bioRxiv : the preprint server for biology

Published: December 03, 2025

EBV infection outcomes determined by monocyte and TREG-driven immune dynamics in an ex vivo pbmc model.

EBV infection outcomes determined by monocyte and TREG-driven immune dynamics in an ex vivo pbmc model.

Journal: PLoS pathogens

Published: November 18, 2025

Long-Term Follow-Up of the Baltimore Experience with Hematopoietic Cell Transplantation for Severe Aplastic Anemia Using Post-Transplantation Cyclophosphamide.

Long-Term Follow-Up of the Baltimore Experience with Hematopoietic Cell Transplantation for Severe Aplastic Anemia Using Post-Transplantation Cyclophosphamide.

Journal: Transplantation and cellular therapy

Published: July 25, 2025

Methylation-specific qPCR for the EBV C promoter to quantify EBV methylation.

Methylation-specific qPCR for the EBV C promoter to quantify EBV methylation.

Journal: Infectious agents and cancer

Published: July 10, 2025

Epigenetic activation of EBV BGLF4 determines antiviral-based regimen response in EBV+CNS lymphoproliferative disease.

Epigenetic activation of EBV BGLF4 determines antiviral-based regimen response in EBV+CNS lymphoproliferative disease.

Journal: Blood neoplasia

Published: June 27, 2025

A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lymphoma.

A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lymphoma.

Journal: Blood

Published: April 15, 2025

A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma.

A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma.

Journal: Blood

Published: April 15, 2025

Prolonged Diagnostic Interval Leads to High Lymphoma Related Mortality in a Prospective Cohort of People with HIV Undergoing Fine Needle Aspiration.

Prolonged Diagnostic Interval Leads to High Lymphoma Related Mortality in a Prospective Cohort of People with HIV Undergoing Fine Needle Aspiration.

Journal: Cancers

Published: February 10, 2025

Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with highdose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy.

Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with highdose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy.

Journal: Haematologica

Published: January 24, 2025

Full-Length Clonal Immunoglobulin Rearrangements in cfDNA: Improved Recovery and Sequencing.

Full-Length Clonal Immunoglobulin Rearrangements in cfDNA: Improved Recovery and Sequencing.

Journal: Clinical chemistry

Published: December 10, 2024

TRBC2-targeting antibody-drug conjugates for the treatment of T cell cancers.

TRBC2-targeting antibody-drug conjugates for the treatment of T cell cancers.

Journal: Nature cancer

Published: November 14, 2024

Showing 1-12 of 182

Last Updated: 09/26/2026